silicon dioxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4284 | 7631-86-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A non-crystalline form of silicon oxide that has absorptive properties. It is commonly used as a desiccating agent and as a stationary phase for CHROMATOGRAPHY. The fully hydrated form of silica gel has distinct properties and is referred to as SILICIC ACID.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 101.06 | 15.44 | 81 | 4949 | 97586 | 50502508 |
| Myelosuppression | 58.45 | 15.44 | 28 | 5002 | 13489 | 50586605 |
| Hepatic function abnormal | 49.18 | 15.44 | 34 | 4996 | 32647 | 50567447 |
| Platelet count decreased | 37.39 | 15.44 | 48 | 4982 | 100678 | 50499416 |
| Neutrophil count decreased | 36.86 | 15.44 | 33 | 4997 | 45993 | 50554101 |
| Exposure to toxic agent | 33.88 | 15.44 | 13 | 5017 | 3645 | 50596449 |
| Liver disorder | 26.51 | 15.44 | 25 | 5005 | 37197 | 50562897 |
| Acute myeloid leukaemia | 21.07 | 15.44 | 15 | 5015 | 15059 | 50585035 |
| Skin lesion | 21.06 | 15.44 | 19 | 5011 | 26708 | 50573386 |
| Laryngeal inflammation | 18.75 | 15.44 | 4 | 5026 | 133 | 50599961 |
| Atrioventricular conduction time shortened | 18.41 | 15.44 | 3 | 5027 | 21 | 50600073 |
| Blood electrolytes increased | 17.37 | 15.44 | 3 | 5027 | 31 | 50600063 |
| Joint stiffness | 17.21 | 15.44 | 18 | 5012 | 30290 | 50569804 |
| Elliptocytosis | 16.96 | 15.44 | 3 | 5027 | 36 | 50600058 |
| Rectal lesion | 16.10 | 15.44 | 3 | 5027 | 49 | 50600045 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 86.91 | 19.44 | 83 | 3233 | 112157 | 29459054 |
| Myelosuppression | 86.49 | 19.44 | 37 | 3279 | 12190 | 29559021 |
| Hepatic function abnormal | 42.11 | 19.44 | 35 | 3281 | 39224 | 29531987 |
| Platelet count decreased | 38.90 | 19.44 | 53 | 3263 | 104619 | 29466592 |
| CADASIL | 33.60 | 19.44 | 6 | 3310 | 67 | 29571144 |
| Magnetic resonance imaging spinal abnormal | 33.28 | 19.44 | 6 | 3310 | 71 | 29571140 |
| Visual evoked potentials abnormal | 32.90 | 19.44 | 6 | 3310 | 76 | 29571135 |
| Central nervous system inflammation | 31.31 | 19.44 | 6 | 3310 | 101 | 29571110 |
| Physical examination abnormal | 31.01 | 19.44 | 7 | 3309 | 268 | 29570943 |
| Saccadic eye movement | 29.87 | 19.44 | 6 | 3310 | 130 | 29571081 |
| Cerebral microangiopathy | 28.29 | 19.44 | 6 | 3310 | 171 | 29571040 |
| Double stranded DNA antibody positive | 27.90 | 19.44 | 6 | 3310 | 183 | 29571028 |
| Lipid metabolism disorder | 24.87 | 19.44 | 6 | 3310 | 308 | 29570903 |
| Acute myeloid leukaemia | 24.83 | 19.44 | 18 | 3298 | 16495 | 29554716 |
| Creatinine renal clearance increased | 22.98 | 19.44 | 6 | 3310 | 425 | 29570786 |
| Exposure to toxic agent | 22.26 | 19.44 | 9 | 3307 | 2566 | 29568645 |
| Infection susceptibility increased | 20.84 | 19.44 | 6 | 3310 | 612 | 29570599 |
| White matter lesion | 20.54 | 19.44 | 6 | 3310 | 644 | 29570567 |
| Spondylolisthesis | 20.14 | 19.44 | 6 | 3310 | 690 | 29570521 |
| CSF protein increased | 19.90 | 19.44 | 6 | 3310 | 719 | 29570492 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 197.51 | 15.75 | 161 | 6653 | 187496 | 64304422 |
| Myelosuppression | 149.13 | 15.75 | 65 | 6749 | 23765 | 64468153 |
| Hepatic function abnormal | 95.70 | 15.75 | 68 | 6746 | 64245 | 64427673 |
| Platelet count decreased | 79.33 | 15.75 | 93 | 6721 | 167618 | 64324300 |
| Exposure to toxic agent | 56.14 | 15.75 | 22 | 6792 | 6137 | 64485781 |
| Neutrophil count decreased | 50.78 | 15.75 | 51 | 6763 | 77145 | 64414773 |
| Acute myeloid leukaemia | 47.78 | 15.75 | 32 | 6782 | 27431 | 64464487 |
| Liver disorder | 40.23 | 15.75 | 38 | 6776 | 53313 | 64438605 |
| Death | 29.00 | 15.75 | 114 | 6700 | 482591 | 64009327 |
| Renal disorder | 22.56 | 15.75 | 23 | 6791 | 35342 | 64456576 |
| Pneumonia | 22.24 | 15.75 | 117 | 6697 | 559459 | 63932459 |
| Bronchopulmonary aspergillosis | 21.28 | 15.75 | 17 | 6797 | 19068 | 64472850 |
| Electrocardiogram QT prolonged | 20.62 | 15.75 | 33 | 6781 | 79415 | 64412503 |
| Pneumonia fungal | 19.54 | 15.75 | 12 | 6802 | 8865 | 64483053 |
| White blood cell count decreased | 18.45 | 15.75 | 47 | 6767 | 157790 | 64334128 |
| Atrioventricular conduction time shortened | 18.23 | 15.75 | 3 | 6811 | 21 | 64491897 |
| Drug ineffective | 17.88 | 15.75 | 39 | 6775 | 840208 | 63651710 |
| Laryngeal inflammation | 17.06 | 15.75 | 4 | 6810 | 193 | 64491725 |
| Blast cell count increased | 16.90 | 15.75 | 6 | 6808 | 1273 | 64490645 |
| Bone marrow failure | 16.89 | 15.75 | 23 | 6791 | 47929 | 64443989 |
| Sepsis | 16.79 | 15.75 | 58 | 6756 | 230283 | 64261635 |
| Elliptocytosis | 16.78 | 15.75 | 3 | 6811 | 36 | 64491882 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D058427 | Hygroscopic Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Peptic ulcer | indication | 13200003 | DOID:750 |
| Heartburn | indication | 16331000 | |
| Indigestion | indication | 162031009 | |
| Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
| Flatulence symptom | indication | 308698004 | |
| Gastric Hypersecretory Conditions | indication | ||
| Hiatal Hernia with Reflux Esophagitis | indication | ||
| Gastrointestinal Radiography Adjunct | indication | ||
| Multiple endocrine adenomas | off-label use | 60549007 | |
| Systemic mast cell disease | off-label use | 397016004 | DOID:349 |
| Stress-Related GI Mucosal Bleeding Prevention | off-label use | ||
| Hypophosphatemia | contraindication | 4996001 | |
| Constipation | contraindication | 14760008 | DOID:2089 |
| Fecal impaction | contraindication | 44635007 | |
| Chronic heart failure | contraindication | 48447003 | |
| Acute nephropathy | contraindication | 58574008 | |
| Diarrhea | contraindication | 62315008 | |
| Hemorrhoids | contraindication | 70153002 | DOID:9746 |
| Oliguria | contraindication | 83128009 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Chronic diarrhea | contraindication | 236071009 | |
| Aluminum intoxication | contraindication | 236546003 | |
| Edema | contraindication | 267038008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4024439 | VUID |
| N0000158434 | NUI |
| 4010521 | VANDF |
| 4020878 | VANDF |
| 4024439 | VANDF |
| C0037098 | UMLSCUI |
| CHEBI:30563 | CHEBI |
| CHEMBL2108563 | ChEMBL_ID |
| D012822 | MESH_DESCRIPTOR_UI |
| DB11132 | DRUGBANK_ID |
| ETJ7Z6XBU4 | UNII |
| 24261 | PUBCHEM_CID |
| 9771 | RXNORM |
| NOCODE | MMSL |
| 005872 | NDDF |
| D058428 | MESH_DESCRIPTOR_UI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| E-Z-GASII | HUMAN OTC DRUG LABEL | 4 | 10361-793 | GRANULE, EFFERVESCENT | 10 mg | ORAL | OTC monograph final | 11 sections |
| SILICEA | HUMAN OTC DRUG LABEL | 1 | 44911-0183 | LIQUID | 200 [hp_C] | ORAL | unapproved homeopathic | 9 sections |
| Silicea | HUMAN OTC DRUG LABEL | 1 | 44911-0186 | LIQUID | 30 [hp_C] | ORAL | unapproved homeopathic | 9 sections |
| DizzinessHP | HUMAN OTC DRUG LABEL | 9 | 44911-0187 | LIQUID | 30 [hp_X] | ORAL | unapproved homeopathic | 9 sections |
| NANO SILVER TOOTHPASTE | HUMAN OTC DRUG LABEL | 3 | 45163-451 | PASTE | 14 g | ORAL | OTC monograph final | 5 sections |
| Type 3 Sinus Max | HUMAN OTC DRUG LABEL | 4 | 50169-0005 | TABLET, ORALLY DISINTEGRATING | 200 [hp_C] | ORAL | unapproved drug other | 9 sections |
| BAMBOO SALT Eunganggo Jook Yeom Toothpaste | HUMAN OTC DRUG LABEL | 7 | 53208-459 | PASTE | 20 g | DENTAL | OTC monograph not final | 4 sections |
| BAMBOO SALT Eunganggo Jook Yeom | HUMAN OTC DRUG LABEL | 7 | 53208-505 | PASTE | 20 g | DENTAL | OTC monograph not final | 8 sections |
| Simethicone | HUMAN OTC DRUG LABEL | 2 | 54868-5620 | SOLUTION/ DROPS | 3.70 mg | ORAL | OTC MONOGRAPH FINAL | 8 sections |
| SILICEA | HUMAN OTC DRUG LABEL | 1 | 54973-3112 | TABLET | 30 [hp_X] | ORAL | unapproved homeopathic | 12 sections |
| SILICEA | HUMAN OTC DRUG LABEL | 1 | 54973-8081 | TABLET | 6 [hp_X] | ORAL | unapproved homeopathic | 12 sections |
| 10 Parasite Detox | HUMAN OTC DRUG LABEL | 15 | 55146-010 | LIQUID | 30 [hp_C] | ORAL | unapproved homeopathic | 9 sections |
| CS Bone | HUMAN OTC DRUG LABEL | 11 | 57955-0211 | LIQUID | 10 [hp_X] | ORAL | unapproved homeopathic | 9 sections |
| Pediacare SIMETHICONE ANTIGAS | HUMAN OTC DRUG LABEL | 2 | 59556-853 | EMULSION | 0.01 g | ORAL | OTC monograph final | 11 sections |
| PediaCare Gas Relief Drops Dye Free | HUMAN OTC DRUG LABEL | 2 | 63029-811 | LIQUID | 0.01 g | ORAL | OTC MONOGRAPH FINAL | 11 sections |
| Gelusil | HUMAN OTC DRUG LABEL | 4 | 65197-300 | TABLET, CHEWABLE | 1 mg | ORAL | OTC monograph final | 13 sections |
| 2080 Dentistry Night Fresh | HUMAN OTC DRUG LABEL | 1 | 67225-0009 | PASTE, DENTIFRICE | 15 g | DENTAL | OTC monograph final | 13 sections |
| 2080 Dentistry Night Repair | HUMAN OTC DRUG LABEL | 1 | 67225-0010 | PASTE, DENTIFRICE | 15 g | DENTAL | OTC monograph final | 13 sections |
| EVERTOX SPECIAL BATH PREPARATIONS | HUMAN OTC DRUG LABEL | 1 | 69474-1001 | POWDER | 20 g | TOPICAL | unapproved drug other | 7 sections |
| Finefra Tooth | HUMAN OTC DRUG LABEL | 2 | 69653-050 | PASTE, DENTIFRICE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| Finefra Black Tooth | HUMAN OTC DRUG LABEL | 2 | 69653-100 | PASTE, DENTIFRICE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| Finefra Black Tooth | HUMAN OTC DRUG LABEL | 2 | 69653-110 | PASTE, DENTIFRICE | 20.25 g | TOPICAL | unapproved drug other | 8 sections |
| Finefra Kids Tooth | HUMAN OTC DRUG LABEL | 2 | 69653-120 | PASTE, DENTIFRICE | 9.10 g | TOPICAL | unapproved drug other | 8 sections |
| Alegria Neo | HUMAN OTC DRUG LABEL | 2 | 70406-020 | PASTE, DENTIFRICE | 2.80 g | TOPICAL | unapproved drug other | 8 sections |
| Olea Olidental | HUMAN OTC DRUG LABEL | 1 | 70417-002 | PASTE | 170 mg | ORAL | unapproved drug other | 8 sections |
| Mongdies raspberry baby tooth | HUMAN OTC DRUG LABEL | 1 | 70477-080 | PASTE, DENTIFRICE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| Exoden Cavity | HUMAN OTC DRUG LABEL | 3 | 70602-005 | PASTE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| Exoden Sensitive | HUMAN OTC DRUG LABEL | 2 | 70602-006 | PASTE | 2.50 g | TOPICAL | unapproved drug other | 8 sections |
| Exoden Gum | HUMAN OTC DRUG LABEL | 2 | 70602-007 | PASTE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| Exoden White | HUMAN OTC DRUG LABEL | 2 | 70602-008 | PASTE | 15 g | TOPICAL | unapproved drug other | 8 sections |